|
[Related PubMed/MEDLINE]
Total Number of Papers: 2134
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. |
AGC, CERs, ICERs, OS, PFS |
| 2 |
2020 |
Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. |
CI, EGFR, NSCLC, OS, PFS, PR, TKI |
| 3 |
2020 |
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). |
DLTs, EWS, RP2D, TMZ |
| 4 |
2020 |
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). |
CPS, IHC, TRAE |
| 5 |
2020 |
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). |
CR, CTCAE, DCR, EAP, irAEs, NSCLC, ORR, OS, PD, PFS, PR, RECIST |
| 6 |
2020 |
Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. |
AUCs, CR, CT, DCA, HCC, NFH, PD, PR, SYUCC, TACE, ZHHAJU |
| 7 |
2020 |
Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. |
CB |
| 8 |
2020 |
Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis. |
AEs, HFS, PFS, PR, RR-DTC, WS |
| 9 |
2020 |
[Application of endoscopic tattooing with carbon nanoparticlet in the treatment for advanced colorectal cancer]. |
ACRC, CR, PD, PR |
| 10 |
2019 |
18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. |
CR, DS, HL, PD, PR |
| 11 |
2019 |
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. |
CT, F-FDG, PD, PR |
| 12 |
2019 |
68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. |
NETs, PD, PFS, PR |
| 13 |
2019 |
A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. |
LCH, PD |
| 14 |
2019 |
A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. |
CRC, DLTs, EGFR, MTD, PR |
| 15 |
2019 |
A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. |
CB, CR, CTCAE, EORTC, LC, MPR-OC, ORR, PR, PTV, RTOG, SBRT |
| 16 |
2019 |
A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy. |
mRCC, OS, PD, PR, RCC, TTP |
| 17 |
2019 |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
CI, DCR, mTOR, mTORC1, NET, PR, SSA |
| 18 |
2019 |
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). |
HMA, MDS |
| 19 |
2019 |
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. |
DL, Inf.U, PR, rec |
| 20 |
2019 |
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. |
CPK, DLTs, GIST, OS, PFS, TEAE, TKIs |
| 21 |
2019 |
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. |
DLT, GD, GDC, Gr, MTD, PR, RPTD, TEAEs |
| 22 |
2019 |
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors. |
GC, HCC, TEAE |
| 23 |
2019 |
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. |
CHOAnome, DL, DLT, GBM, HGG, PR |
| 24 |
2019 |
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. |
CR, OS, PBLs, PFS, PR, RCR, SIG |
| 25 |
2019 |
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. |
AE, CR, DLT, MR, PD, PR, VGPR |
| 26 |
2019 |
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. |
AEs, MTD, mTOR, NSCLC, PFS, PR |
| 27 |
2019 |
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. |
DLT, FGF, GIST |
| 28 |
2019 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. |
AE's, CI, DDLS, DSRCT, LMS, MLS, ORRs, PFS, PR, SS, STS |
| 29 |
2019 |
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. |
CR, HMAs, MDS, PR |
| 30 |
2019 |
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). |
CI, MPM, OS, PFS-6, PR |
| 31 |
2019 |
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. |
ASPS, CI, ORR, OS, PET, PFS, PR |
| 32 |
2019 |
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. |
AEs, CR, ECOG, HN, mFUP, mOS, mPFS, PR, SGC |
| 33 |
2019 |
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. |
CBR, SINE, TNBC |
| 34 |
2019 |
A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. |
CR, OS, PR, SBRT, UC |
| 35 |
2019 |
A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer. |
CBR, CBR, CR, DCR, HIFU, ORR, OS, PFS, PR |
| 36 |
2019 |
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. |
BID, Choi, IQR, M-SFT, ORR, OS, PFS, PR, RECIST, SFT |
| 37 |
2019 |
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. |
CR, HCC, OS, PD, PR, VEGF, vWF, VWF |
| 38 |
2019 |
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. |
ECOG, HCC, MTD, PFS, Plk1, PR, siRNA |
| 39 |
2019 |
Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study. |
AFP, PR, PRETEXT, RFS |
| 40 |
2019 |
Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. |
CI, OS, PFS, PR |
| 41 |
2019 |
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. |
AEs, CI, DCR, PR, RECIST, SCLC |
| 42 |
2019 |
Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. |
CI, DCR, HBV, HCC, ORR, OS, PD, PR, TTP |
| 43 |
2019 |
Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. |
NSCLC, ORR, PD, PR |
| 44 |
2019 |
Assessment of spatial tumor heterogeneity using CT growth patterns estimated by tumor tracking on 3D CT volumetry of multiple pulmonary metastatic nodules. |
CT |
| 45 |
2019 |
Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population. |
AUC, CR, DHPLC, ESCC, LNM, PD, PFS, PR, ROC |
| 46 |
2019 |
Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. |
CAR, CRs, CRS, DLBCL, PET, PR |
| 47 |
2019 |
Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images. |
CRPC, MVol, PD, PR, PSA, SVol |
| 48 |
2019 |
Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control. |
CIRT, CR, DPFS, IMRT, LC, NPC, OS, PR |
| 49 |
2019 |
Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. |
CR, DEE, HCC, mRECIST, PD, PR |
| 50 |
2019 |
Carbon ions therapy as single treatment in chordoma of the sacrum. Histologic and metabolic outcome studies. |
CIRT, LC, OS, PFS, PR, SC |
| 51 |
2019 |
Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). |
ASPS, PR, RECIST, VEGF |
| 52 |
2019 |
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. |
HI, IPSS, MDS, WPSS |
| 53 |
2019 |
Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. |
CR, DF, MRI, MTX, PD, PFS, PR, VNL |
| 54 |
2019 |
Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis. |
CEA, CR, CYFRA21-1, PD, PR |
| 55 |
2019 |
Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. |
CR, DCR, DDGP, EBV, ORR, OS, PD, PFS, PR |
| 56 |
2019 |
Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients. |
--- |
| 57 |
2019 |
Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. |
GBM, miR, PD, PR, qPCR |
| 58 |
2019 |
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. |
CR, FFPE, ICI, OS, PD-1, PD-L2, PFS, PR, QIF, RT-qPCR, RUO |
| 59 |
2019 |
Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. |
CR, NHL, PD, PR, RIT, SPD, SUV |
| 60 |
2019 |
Concurrent Bronchial Artery and Posterior Inferior Cerebellar Artery Microcatheter Interventional Chemotherapy for Adenocarcinoma of the Lung with Solitary Cerebellar Metastasis. |
CBP, CR, DCR, ORR, PD, PR |
| 61 |
2019 |
Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. |
ADA, PD, PD-1, PR |
| 62 |
2019 |
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety. |
ALK, CR, DCR, NSCLC, ORR, PR |
| 63 |
2019 |
CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study. |
PD, PR |
| 64 |
2019 |
Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib. |
CCK-8, CDKN2B, HCC, PD, PR, RT-qPCR, SP |
| 65 |
2019 |
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. |
CR, PD, PR, TLT |
| 66 |
2019 |
Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? |
CR, HR, MBC, OS, PD, PFS, PR |
| 67 |
2019 |
Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? |
HD, LD, PanNENs, PD, PR |
| 68 |
2019 |
Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. |
cfDNA, MRD, MS, NB, PR |
| 69 |
2019 |
Dysphagia predict the response to second cycle neoadjuvant chemotherapy in first cycle no response esophageal carcinoma. |
CI, CT, ESCC, NAC, OR, PD |
| 70 |
2019 |
Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. |
BMAs, CR, CT, MDA criteria, NRS, PD, PR, RT |
| 71 |
2019 |
Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer. |
CR, DCR, PD, PR, RR |
| 72 |
2019 |
Effects of cyclophosphamide combined with prednisone on TNF-alpha expression in treatment of patients with interstitial lung disease. |
CR, DLCO, FVC, ILD, SGRQ |
| 73 |
2019 |
Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. |
OS, PD, PFS, PPS, PR, RR-DTC, TKIs |
| 74 |
2019 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. |
ACC, AE, mTKI, PR, RR |
| 75 |
2019 |
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. |
AEs, CI, MTCs, PR |
| 76 |
2019 |
Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. |
RCC, VEGFR |
| 77 |
2019 |
Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study. |
aNSCLC, CR, DCR, EC, EGFR, OS, PD, PFS, PR |
| 78 |
2019 |
Efficacy of neoadjuvant chemotherapy and Annexin A3 expression in breast cancer. |
ANXA3, BC, CR, NAC, PD, PR |
| 79 |
2019 |
Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer. |
CR, GC, PR, QOL |
| 80 |
2019 |
Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. |
BR, EORTC, Ga68-PSMA PET-CT, MDA, PCa, PD, PR, PRLT, PSMA, RECIST 1.1 |
| 81 |
2019 |
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. |
CB, CI, CR, EEC, OR, PR |
| 82 |
2019 |
Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma. |
CR, lncRNAs, LUAD, LUSC, NSCLC, PD, PR, RFS, SUMO1, SUMO1P3 |
| 83 |
2019 |
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. |
NETs, OS, PCC, PFS, PGL, PR, PRRT |
| 84 |
2019 |
Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. |
ECOG, HBOT, MSCT, NSCLC, OS, PD, PFS |
| 85 |
2019 |
Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. |
CR, MIBC, NAC, PD, RC, SNd, SNs |
| 86 |
2019 |
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. |
AEs, DCR, MPC, OS, PFS |
| 87 |
2019 |
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. |
mTOR, PK, PR |
| 88 |
2019 |
Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison. |
cfDNA, EGFR, NSCLC, PR, TKIs |
| 89 |
2019 |
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. |
mCRC, PD, PR, RAS-M |
| 90 |
2019 |
Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature. |
--- |
| 91 |
2019 |
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. |
AUC, DCB, ICIs, NDB, PD, PR, SCNA, TMB, WES |
| 92 |
2019 |
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. |
CR, DCR, DSA, FUDR, HAI, mOS, ORR, PR |
| 93 |
2019 |
High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin. |
CR, CSCC, FIGO, PR, VEGF |
| 94 |
2019 |
High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). |
AE, CR, DCR, HSV-1, ORR, PD, PR, T-VEC |
| 95 |
2019 |
Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT. |
CR/PR, dNLR, HPD, ICI, NSCLC, PD |
| 96 |
2019 |
Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. |
BED, CR, HCC, HFRT, IVC, IVC, PD, PR, RA, TT |
| 97 |
2019 |
Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. |
CHT, CR, ES-SCLC, IMRT, OS, PFS, PR, TRT |
| 98 |
2019 |
Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. |
CR, HCC, mRECIST, OR, PD, PR, TACE, TGR |
| 99 |
2019 |
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. |
CR, MHC, NK, PD, PR |
| 100 |
2019 |
Intravoxel incoherent motion (IVIM) for response assessment in patients with osteosarcoma undergoing neoadjuvant chemotherapy. |
ADC, DWI, IVIM, NACT, PD, PR |
|
A Search Service for Abbreviation / Long Form
